Stability of oseltamivir phosphate in SyrSpend SF, Cherry syrup, and SyrSpend SF (for reconstitution)

International Journal of Pharmaceutical Compounding

Volumn 14, Issue 1, 2010, Pages 82-85

  Voudrie II, Mark A ^a   Allen, D Brett ^a  

^a Dynalabs   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG VEHICLE; OSELTAMIVIR; SYRSPEND SF; UNCLASSIFIED DRUG;

ARTICLE; CHERRY SYRUP; CONCENTRATION RESPONSE; DRUG DEGRADATION; DRUG FORMULATION; DRUG POTENCY; DRUG SPECIFICITY; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PRESCRIPTION; ROOM TEMPERATURE; SUSPENSION;

EID: 77950610142     PISSN: 10924221     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. U.S. Department of Health and Human Services. Centers for Disease Control and Prevention. Notifiable Diseases/Deaths in Selected Cities Weekly Information. Morbidity and Mortality Weekly Report. [CDC Website.] November 19, 2009. Available at: www.cdc.gov/mmwr/preview/mmwrhtml/mm5845md.htm. Accessed November 23, 2009.
2. U.S. Department of Health and Human Services. Centers for Disease Control and Prevention. 2009 N1N1 Flu: Situation Update. [CDC Website.] Updated December 18, 2009. Available at: www.cdc.gov/h1n1flu. Accessed November 23, 2009.
3. Buck ML, ed. Children's Medical Center at the University of Virginia. Pediatric Pharmacotherapy Newsletter. 1996; 2(9). Available at: www.healthsystem.virginia. edu/alive/pediatrics/PharmNews/199609.pdf. Accessed November 25, 2009.
4. Winiraski AP, Infeld MH, Tscheme R et al. Preparation and stability of extemporaneous oral liquid formulations of oseltamivir using commercially available capsules. J Am Pharm Assoc 2007; 47(6): 747-755.